Lisanti Capital Growth LLC Lowers Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Lisanti Capital Growth LLC decreased its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 33.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,685 shares of the company's stock after selling 20,280 shares during the period. Lisanti Capital Growth LLC owned approximately 0.08% of PROCEPT BioRobotics worth $3,276,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of PRCT. Raymond James Financial Inc. bought a new stake in PROCEPT BioRobotics during the 4th quarter valued at approximately $1,647,000. Arizona State Retirement System boosted its position in shares of PROCEPT BioRobotics by 1.5% during the fourth quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock valued at $1,150,000 after purchasing an additional 218 shares in the last quarter. Aigen Investment Management LP bought a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at approximately $420,000. Assetmark Inc. purchased a new stake in PROCEPT BioRobotics in the fourth quarter worth $667,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in PROCEPT BioRobotics by 5.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 426,434 shares of the company's stock worth $34,336,000 after purchasing an additional 23,869 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock traded up $1.98 during trading on Tuesday, hitting $59.57. 814,754 shares of the company's stock traded hands, compared to its average volume of 716,972. PROCEPT BioRobotics Co. has a 1 year low of $45.56 and a 1 year high of $103.81. The business has a 50-day simple moving average of $72.02 and a 200-day simple moving average of $79.67. The stock has a market capitalization of $3.27 billion, a P/E ratio of -30.55 and a beta of 1.06. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07.

Remove Ads

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. As a group, analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Wells Fargo & Company restated an "overweight" rating and set a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a "hold" rating and a $95.00 price objective on the stock. Truist Financial reiterated a "buy" rating and set a $90.00 target price (down from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Morgan Stanley cut their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of "Moderate Buy" and an average price target of $94.29.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).